Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

MOUNTAIN VIEW, Calif., Nov. 8, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology (ACR).  CCX354 is an orally-active small molecule that specifically targets and inhibits the chemokine receptor known as CCR1, which is implicated in the development and progression of rheumatoid arthritis (RA).  Results showed that CCX354 was safe and well tolerated by patients with RA in this clinical trial, and demonstrated clinical and biological activity at a dose of 200 mg once daily.  These data were highlighted today in a late-breaker oral presentation in Chicago entitled "Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase II Rheumatoid Arthritis Study".

"The initial cloning and characterization of CCR1 as well as the chemokine known as RANTES, one of the main ligands for CCR1, was accomplished by the founder of ChemoCentryx over twenty years ago," stated Paul-Peter Tak, M.D., Ph.D., Lead Investigator and Professor at AMC/University of Amsterdam, currently also Senior Vice President/Head, Therapy Area ImmunoInflammation at GlaxoSmithKline.  "Although there has been strong evidence implicating CCR1 in the pathology of RA, this is the first time that an investigational CCR1 antagonist has successfully demonstrated clinical efficacy in patients with this disease."

The results reported from this study, known as the CARAT-2 clinical trial, show that patients who met inclusion criteria at the start of dosing (Day 1 eligible) had an ACR20 response at Week 12 of 56% in patients receiving 200 mg CCX354 once daily compared to 44% in patients receiving 100 mg twice daily, and 30% in patients receiving placebo. The difference between 200 mg once daily and placebo was statistically significant (p=0.014). The decrease in CRP, a marker of inflammation, was statistically significant in the 200 mg QD group com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Transportation Insight, a leading global ... client, DSI Systems Inc., are featured in the ... in the cover story emphasizing technology as the ... editorial illustrates how Transportation Insight implemented its ... growth and success of DSI,s complex supply chain. ...
(Date:5/4/2015)... , May 4, 2015 DePuy Synthes CMF* ... Repair, the first commercially available biosynthesized dural replacement derived ... is a part of the DePuy Synthes Companies of ... tissue membrane that covers and protects the brain and ... to allow surgeons to access the brain. A dural ...
(Date:5/4/2015)... -- The board of directors of Eli Lilly and Company (NYSE: ... quarter of 2015 of $0.50 per share on outstanding common ... 2015, to shareholders of record at the close of business ... Lilly is a global healthcare leader that unites caring with ... We were founded more than a century ago by a ...
Breaking Medicine Technology:Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3
... BOZEN, Sud-Tirol, Italy , July 20, 2010 ... rights in Spain and Portugal to world-leading IV,Therapy company ... at Vall d,Hebron University Hospital in Barcelona in November,2010 . ... "We are ...
... , WILMINGTON, Del. , July 20 ... Be Heard… Living With Depression contest, ... Bipolar Support Alliance (DBSA), encourages people with depressive symptoms of ... depression) to share their stories of success.  Submissions are now ...
Cached Medicine Technology:Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 2Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 3Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital 4National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 2National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 3National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 4National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 5National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 6National Contest Encourages People with Depressive Symptoms of Bipolar Disorder or Major Depressive Disorder to Speak Out 7
(Date:5/4/2015)... Malibu Biotech Systems LLC salutes ... KissSafe™ is the first personal hygiene product dedicated ... adding fresh breath appeal. KissSafe™ contains an FDA-approved ... in the mouth and oral cavity before and ... possess additional wellness benefits. KissSafe’s proprietary prevent-tech will ...
(Date:5/4/2015)... In a continuing effort to remain a leading ... the founder of Choices Recovery in South Bend, IN, ... the Oscars” celebration held on February 21st, 2015, ... the luxurious Beverly Hilton Hotel. , Organized by ... placement in TV and film, this daylong event gathered ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Getting ... to manage their health is critical to achieving the ... and reducing costs, but this will require a shift ... change also demands that health systems move beyond their ... who took part in the third live meeting of ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3
... Symptoms of low levels of testosterone include erectile ... and anemia.// Testosterone replacement therapy is designed to ... The therapy may be offered as an injection, ... replacement therapy does not increase a man’s risk ...
... less likely to develop high blood pressure say researchers based ... study researchers analyzed data from two large studies, which included ... questionnaires, which asked about their folate and supplemental folic acid ... the start of the study. It was found that younger ...
... research suggests weight loss may be an early sign ... begins before the onset of // definite dementia symptoms ... loss in the elderly is common and may be ... documented in people who already have dementia. For the ...
... has brought with it a new lease of life for ... the uphill struggle doesn’t stop with finding a matching donor. ... has shown that despite all high tech matching done for ... Transplant surgeon Ignazio Marino, M.D., of Thomas Jefferson University Hospital ...
... the use of estrogen replacement therapy with a lower risk ... is known as a good indicator of exposure to estrogen. ... BMD related to the risk of cognitive problems. All of ... of the study. Researchers then measured their BMD at several ...
... the reason some adolescents experience depression could be abnormal ... between ages 13 to 18, half of who had ... was performed to measure the volume of each teen’s ... hippocampus of patients with depression was, on average, 17 ...
Cached Medicine News:
... Supplemental Confirmatory (Western Blot): The Genetic Systems ... test for the detection of antibodies to HIV-1. ... strain of HIV-1 grown in the CEM cell ... is devoid of HLA Class ll antigens, helps ...
... Screening: The Procleix System has added ... the nation's blood supply. It utilizes innovative ... and a unique nucleic acid amplification technique ... can simultaneously detect the presence of HIV-1 ...
... Diagnostic, Non-Donor Screen. Vironostika HIV assays provide ... additional testing and confirmation. Vironostika HIV-1 ... for the detection of antibody to HIV-1 ... Oral Fluid Vironostika HIV-1 Microelisa System ...
... an OraSure HIV-1 Oral Specimen Collection Device is ... for HIV-1 antibodies. Testing with the OraSure HIV-1 ... needles and has been shown to be more ... specially treated cotton fiber pad attached to a ...
Medicine Products: